Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Trial Profile

Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Defactinib (Primary) ; Gemcitabine; Pembrolizumab
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jan 2018 The dose escalation cohort has been completed with a total of 17 patients with refractory solid tumors being enrolled. The expansion cohort (PDAC only) is ongoing.
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 23 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top